Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Saved in:
| Title: | Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. |
|---|---|
| Authors: | Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Albiges L; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France., Tomczak P; Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland., Suárez C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Voss MH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Velasco G; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Chahoud J; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Mochalova A; Department of Chemotherapy, Clinical Hospital Number 1 MEDSI, Moscow, Russia., Procopio G; Department of Medical Oncology, Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy., Mahammedi H; Department of Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France., Zengerling F; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany., Kim C; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea., Osawa T; Department of Urology, Hokkaido University Hospital, Sapporo, Japan., Angel M; Department of Genitourinary Cancer, Instituto Alexander Fleming, Buenos Aires, Argentina., Gupta S; Genentech, South San Francisco, CA, USA., Khan O; Roche Product, Welwyn Garden City, UK., Bergthold G; F Hoffmann-La Roche, Basel, Switzerland., Liu B; Genentech, South San Francisco, CA, USA., Kalaitzidou M; Roche Product, Welwyn Garden City, UK., Huseni M; Genentech, South San Francisco, CA, USA., Scheffold C; Exelixis, Alameda, CA, USA., Powles T; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu. |
| Source: | Lancet (London, England) [Lancet] 2023 Jul 15; Vol. 402 (10397), pp. 185-195. Date of Electronic Publication: 2023 Jun 05. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
